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Abstract: Introduction: Coronary artery disease (CAD) is among the most common cardiovascular diseases (CVDs),
caused by the formation of plaques of lipids, calcium, and inflammatory cells. In Iran, CAD is responsible for
about 50% of all deaths per year. There is also a probability of the role of androgens deficiency in CAD in men.
We aimed to systematically review all the related original studies to achieve an overall insight into the associa-
tions of testosterone and CAD in Iranian men. Methods: MedLine, Web of Science, Scopus, and Google scholar
databases were searched from inception to January 2021. All types of studies on Iranian men older than 40 years
of age, reporting results of comparing testosterone in normal individuals and those with CAD were included.
The main findings of the articles were compared to achieve an overall statement. Results: Ultimately, six studies
were included. Most (66.7%) had directly stated that lower levels of testosterone are associated with CAD or the
level of testosterone is lower in patients with proven CAD. Among them, in 3 (50%) studies, the mean age of the
participants had no significant difference between patients with CAD and the normal group. Conclusion: It is
clear that low testosterone level is associated with increased risk of cardiovascular events but it is not definitely
determined whether it is independent of age in Iranian men. Further well-designed studies are needed to clearly
exclude all confounding variables including age and show the net effect of testosterone on CAD.
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1. Introduction
Coronary artery disease (CAD) is one the most common
cardiovascular diseases (CVDs), caused by the formation of
plaques of lipids, calcium, and inflammatory cells. These ar-
terial plaques lead to narrowing the blood supply of heart
muscles and cause angina pectoralis (1). CAD involves all the
people around the world and more than 18.2 million individ-
uals are living with this disease in the USA. This disease is also
one of the most important causes of mortality throughout the
world (2-4). In Iran, CAD is responsible for about 50% of all
death per year (5). Diabetes, hypertension, hyperlipidemia,
obesity, Homocystinuria, smoking, psychological distresses,
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and age are among the most common risk factors of CAD (4,
6, 7). In men, there is also a probability of the role of andro-
gens deficiency in CAD (8). Testosterone as an important an-
drogen plays a special role in the health of the cardiovascular
system. Moreover, there is a footprint of significant testos-
terone deficiency in many chronic diseases (9, 10).
Recent studies have focused on the association between re-
duced androgens (mostly testosterone) and CAD but their re-
sults have lots of controversies. For example, some studies
have mentioned that the level of testosterone is correlated
with the incidence and the severity of CAD (11), or hypog-
onadism and low testosterone level are risk factors of mortal-
ities because of CVDs (10, 12). On the other hand, there are
some studies that show different results and reject any asso-
ciation between the level of testosterone and incidence and
prognosis of CAD (13, 14).
According to these controversial results and lack of inte-
grated data in this field, this study aimed to systematically
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review all the related original studies to achieve an overall
insight about the associations of testosterone and CAD in
Iranian men to be considered as a base for some preventive
measures such as testosterone replacement therapy (TRT).
2. Methods
2.1. Search strategy
Two researchers with a medical background conducted an
independent electronic search. Medline, Web of Science,
Scopus and, Google scholar from inception to January 2021
were searched. The search keywords were Testosterone OR
Androgenic AND Coronary or myocardial AND Iran. The
search strategy for PubMed was: ((("Coronary"[All Fields]
or "myocardial"[All Fields]) AND ("Testosterone"[All Fields])
OR ("Androgenic"[All Fields])) AND Iran). Databases in Per-
sian including scientific information database (SID) and Ma-
giran were also searched.
2.2. Inclusion and exclusion criteria
To find original articles about the association of testosterone
level and CAD incidence or severity in the Iranian adult pop-
ulation, the eligibility criteria based on PICOS (i.e., partici-
pants, interventions, comparisons, outcomes, and study de-
sign) were all types of studies on men older than 40 years
of age, with any effect size about comparing testosterone in
normal individuals and those with CAD. Articles with no full
text and studies that had defined the CAD rather than stan-
dard clinical criteria were excluded.
2.3. Data extraction and reporting
We collected the author’s identification, year of publication,
province of the study, Study type, CAD criteria, number and
age of the participants (CAD vs normal), main measure-
ments, and main findings of articles in a table and then com-
pared them in result section to achieve an overall statement.
Quality assessment of the studies was performed using the
Newcastle-Ottawa Scale (NOS) checklist (15). Since there was
no common effect size among the included studies, Meta-
analysis was not applicable.
3. Results
The initial search identified 563 studies, then 95 duplications
were removed and the remaining 468 studies were evaluated.
Among them, 15 studies matched the inclusion criteria. Fi-
nally, six studies were included (figure 1). The search results
had an almost perfect agreement (kappa= 0.91) between the
two researchers.
Although there was a remarkable heterogeneity among the
included studies, as shown in table 1, most (66.7%) had di-
rectly stated that lower levels of testosterone were associated
with CAD or the level of Testosterone is lower in patients
with proven CAD. There was only one (16.7%) study showing
no significant correlation between two forms of testosterone
(TT and FT) and the presence or severity of CAD. Another
study showed that a higher level of TT (22.1 to 43.3 ng/l) was a
risk factor for CAD. Four (66.7%) studies were cross-sectional
and two (33.3%) studies had a case-control design. The most
common criterion used for categorization of patients into
CAD or normal groups was having ≥1 affected (≥50% steno-
sis) coronary vessels (4 studies [66.7%]). In 3 (50%) studies
the mean age of the participants had no significant differ-
ence between CAD patients and the normal group, so based
on these studies it can be stated that the risk of low testos-
terone for CAD may be independent of age.
4. Discussion
Based on our review low testosterone level can be considered
as a potential risk factor for CAD, there are some included
studies among our results that show the independent effect
of testosterone on this disease. Although testosterone defi-
ciency is not considered as a major risk factor for CAD, it is
generally accepted that the male factor is a major risk fac-
tor to develop cardiovascular disease and testosterone level
gradually declines with increasing age (9). Cardiovascular
disease is three folds more common in men than women
and it develops a decade earlier in men (21). There is com-
pelling evidence that showed low testosterone level is asso-
ciated not only with increased risk of cardiovascular events
but also with cardiac mortality and overall mortality (20, 22,
23). Allameh and colleagues reported that serum free testos-
terone level is lower in patients with CAD (13) this relation-
ship might be attributed to the effects of age and diabetes
mellitus on the androgen level. Multiple studies showed that
there is an inverse relationship between coronary artery cal-
cium (CAC) score and testosterone level (24, 25). Testos-
terone level is an independent predictor of CAD severity
when assessed via Gensini score (23, 26). Men younger than
45 years with premature CAD have also been found with low
testosterone levels compared with controls (27). Separham
and co-workers reported that there was a significant positive
correlation between left ventricular function and free testos-
terone (17). Davoodi and colleagues (18) showed that serum
testosterone level is significantly lower in patients with se-
vere heart failure. Men in the highest tertiles of testosterone
and bioavailable testosterone had a lower relative risk of ab-
dominal aortic atherosclerosis than men in the lowest ter-
tile (28). Some studies have shown a negative correlation
between the degree of angiographic coronary disease and
testosterone levels (29). Despite many studies showing the
relationship between testosterone level and cardiovascular
disease, several studies such as Davoodi and colleagues (19)
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failed to show a cause and effect relationship between testos-
terone level and cardiovascular events because testosterone
could be a marker for general well-being and quality of health
(23) so it might have no direct effect on CAD and CVD events.
Malkin and co-workers reported that low testosterone level
increases the risk of cardiovascular events and it influences
life expectancy and showed that testosterone level could be a
prognostic factor in patients with cardiovascular disease (30).
On the other hand, Fallah and colleagues (16) reported that
although testosterone has a preventive effect at the low stan-
dard level, higher testosterone levels increase the risk of car-
diac events. Budoff and co-workers showed that testosterone
therapy was associated with increased non-calcified plaque
compared with placebo in the coronary artery but it did not
increase CAC score or major cardiac events (31). Some other
studies showed that testosterone therapy could increase the
risk of cardiac events in patients with known cardiac disease
(32). Several Meta-analyses reported that testosterone ther-
apy had neutral effects on the occurrence of major cardio-
vascular events, and had various small effects on lipid levels
(33-35).
5. Conclusion
It is clear that low testosterone level is associated with in-
creased risk of cardiovascular events but it is not definitely
determined that is independent of age in Iranian men. Fur-
ther well-designed studies are needed to clearly exclude all
confounding variables including age and show the net effect
of testosterone on CAD.
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Figure 1: Flow chart of study selection following PRISMA guidelines.
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CAD criteria Number and age
of Participants
(CAD vs Normal)









191 vs 94 Mane
age: 41.6 vs 39.3
(p<0.001)
FT and TT and
Coronary angiogram,
Gensini score
(cut-off for low TT
was 2.5 ng/L)
The association between low TT and
CAD is significant (p≤0.001). There
was a significant negative correlation
between Gensini score and TT (r=








388 vs 114 Mane
age: 57 vs 52.9
(p<0.001)
TT and FT and
coronary angiogram
TT level divided into
3 groups; low (0 to 7),
medium (7.1 to 22),
and high (22.1 to
43.3).
TT showed a significant preventive
effect in low levels and a risk factor








200 vs 135 Mane





The serum levels of FT & DHEA-S were
significantly higher in the control
group than in the CAD group (P=0.048
P<0.0001 respectively). SHBG was
higher in the CAD group than in the
control group (p=0.007). -These
significant differences were possibly
because of the effects of age and









35 vs 13 Mean




-The serum levels of FT, was lower in
patients with complete ST-resolution
compared to those with incomplete
ST-resolution (p=0.04). -A significant
positive correlation was observed
between the left ventricular function









388 vs 114 Mane





There was no significant correlation
between FT, TT, DHEA-S and the







30 vs 30 55.9 vs
56.5 (p =0.881).
Testosterone Normal
range: 3 to 10 ng/L
-Serum levels of testosterone in CAD
group were significantly lower than in
control group (p=0.0001). -In CAD
group, 21 (70%) patients had
testosterone levels below the normal
level while in control group all the
men had normal level of testosterone.
TT: Total Testosterone; FT: Free Testosterone; DHEA-S: Dehydroepiandrosterone sulfate;
SHBG: Sex Hormone Binding Globulin; CAD: Coronary Artery Disease; EF: Ejection Fraction .
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